Concert Pharmaceuticals (CNCE) Short Interest Ratio & Short Volume

Short interest is the volume of Concert Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of February 15th, investors have sold 1,080,000 shares of CNCE short. Learn More on Concert Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CNCE shares currently have a short interest ratio of 1.0. Learn More on Concert Pharmaceuticals's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Concert Pharmaceuticals: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Concert Pharmaceuticals saw a decline in short interest during the month of February. As of February 15th, there was short interest totaling 1,080,000 shares, a decline of 58.5% from the previous total of 2,600,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Concert Pharmaceuticals: Adlai Nortye Ltd. (0.02%), Atai Life Sciences (4.81%), ADC Therapeutics SA (1.81%), Corbus Pharmaceuticals Holdings, Inc. (4.58%), PepGen Inc. (1.48%), Mereo BioPharma Group plc (1.86%), Organogenesis Holdings Inc. (9.35%), Neoleukin Therapeutics, Inc. (0.35%), Heron Therapeutics, Inc. (17.00%), Shattuck Labs, Inc. (4.40%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Enbridge Inc. ($4.09 billion), Occidental Petroleum Co. ($3.00 billion), T. Rowe Price Group, Inc. ($2.35 billion), Coinbase Global, Inc. ($2.30 billion), Paramount Global ($2.04 billion), Etsy, Inc. ($1.90 billion), Voya Financial, Inc. ($1.77 billion), CarMax, Inc. ($1.67 billion), Royal Caribbean Cruises Ltd. ($1.58 billion), and Monolithic Power Systems, Inc. ($1.47 billion). View all of the most shorted stocks.

Short selling CNCE is an investing strategy that aims to generate trading profit from Concert Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Concert Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CNCE, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CNCE, twice per month. The most recent reporting period available is February, 15 2023.